BR112021013944A2 - - Google Patents

Info

Publication number
BR112021013944A2
BR112021013944A2 BR112021013944A BR112021013944A BR112021013944A2 BR 112021013944 A2 BR112021013944 A2 BR 112021013944A2 BR 112021013944 A BR112021013944 A BR 112021013944A BR 112021013944 A BR112021013944 A BR 112021013944A BR 112021013944 A2 BR112021013944 A2 BR 112021013944A2
Authority
BR
Brazil
Application number
BR112021013944A
Other languages
Portuguese (pt)
Other versions
BR112021013944A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112021013944A2 publication Critical patent/BR112021013944A2/pt
Publication of BR112021013944A8 publication Critical patent/BR112021013944A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2334—Interleukin-34 (IL-34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR112021013944A 2019-01-15 2020-01-15 Polipeptídeos de interleucina-34 (il-34) mutada e usos dos mesmos em terapias BR112021013944A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305046 2019-01-15
PCT/EP2020/050920 WO2020148338A1 (en) 2019-01-15 2020-01-15 Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy

Publications (2)

Publication Number Publication Date
BR112021013944A2 true BR112021013944A2 (en:Method) 2021-11-21
BR112021013944A8 BR112021013944A8 (pt) 2023-02-07

Family

ID=65228484

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021013944A BR112021013944A8 (pt) 2019-01-15 2020-01-15 Polipeptídeos de interleucina-34 (il-34) mutada e usos dos mesmos em terapias

Country Status (13)

Country Link
US (1) US20220098264A1 (en:Method)
EP (1) EP3911670B1 (en:Method)
JP (2) JP7645185B2 (en:Method)
KR (1) KR20210121077A (en:Method)
CN (1) CN113508129B (en:Method)
AU (1) AU2020208909B2 (en:Method)
BR (1) BR112021013944A8 (en:Method)
CA (1) CA3126741A1 (en:Method)
ES (1) ES3011707T3 (en:Method)
IL (1) IL284868B2 (en:Method)
MX (1) MX2021008525A (en:Method)
SG (1) SG11202107606VA (en:Method)
WO (1) WO2020148338A1 (en:Method)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023246908A1 (zh) * 2022-06-21 2023-12-28 四川大学华西医院 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用
CN115819614B (zh) * 2022-06-21 2024-02-23 四川大学华西医院 一种基于il34的嵌合抗原受体免疫细胞制备及其应用
CN115252764A (zh) * 2022-08-09 2022-11-01 南方医科大学 一种白介素在制备治疗急性髓系白血病的药物中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR520E (fr) 1901-11-13 1903-01-26 Bermont Victor Etienne Procédé industriel d'extraction directe du zinc contenu dans les minerais oxydés, et plus spécialement dans la smithsonite (znco3) et la calamine (h2zn2sio5)
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
AU5344190A (en) 1989-03-21 1990-10-22 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
WO1994019478A1 (en) 1993-02-22 1994-09-01 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
EP0753069A1 (en) 1994-04-15 1997-01-15 Targeted Genetics Corporation Gene delivery fusion proteins
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
HRP20010551B1 (hr) 1998-12-23 2013-05-31 Pfizer Inc. Humana monoklonalna antitijela za ctla-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
KR20020047132A (ko) 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
DE60135029D1 (de) 2000-07-03 2008-09-04 Bristol Myers Squibb Co Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
CA2461730C (en) 2001-10-19 2012-05-15 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
KR20110140142A (ko) 2002-10-17 2011-12-30 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US7488802B2 (en) 2002-12-23 2009-02-10 Wyeth Antibodies against PD-1
WO2006012451A2 (en) * 2004-07-22 2006-02-02 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment
CA3151350A1 (en) 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CA3201163A1 (en) 2005-07-01 2007-01-11 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
PL1962886T6 (pl) 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US20110223188A1 (en) 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
EP2927240A1 (en) 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
PT4209510T (pt) 2008-12-09 2024-04-02 Hoffmann La Roche Anticorpos anti-pm-l1 e a sua utilização para a melhoria do funcionamento das células t
EP2417984B1 (en) 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Method for treatment of blood tumor using anti-tim-3 antibody
US8289808B2 (en) 2009-04-16 2012-10-16 Chevron U.S.A., Inc. System and method to estimate compressional to shear velocity (VP/VS) ratio in a region remote from a borehole
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
ES2646863T3 (es) 2009-11-24 2017-12-18 Medimmune Limited Agentes de unión específica contra B7-H1
PT2581113T (pt) 2010-06-11 2018-07-04 Univ Kyushu Nat Univ Corp Anticorpo anti-tim-3
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
AU2012344260B2 (en) 2011-11-28 2017-09-07 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
WO2014150677A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase (ido)
SG10201800508SA (en) 2013-09-06 2018-02-27 Aurigene Discovery Tech Ltd 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
TR201809838T4 (tr) 2013-09-06 2018-07-23 Aurigene Discovery Tech Ltd İmmünomodülatörler olarak 1,2,4-oksadiazol türevleri.
EP3169350B1 (en) * 2014-07-17 2019-01-09 INSERM - Institut National de la Santé et de la Recherche Médicale An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases
CN107810012A (zh) * 2015-06-02 2018-03-16 豪夫迈·罗氏有限公司 使用抗il‑34抗体治疗神经疾病的组合物和方法
CN106084030B (zh) * 2016-04-25 2019-11-08 北京大学 一种提高白细胞介素il-34热稳定性的方法

Also Published As

Publication number Publication date
EP3911670A1 (en) 2021-11-24
CA3126741A1 (en) 2020-07-23
US20220098264A1 (en) 2022-03-31
SG11202107606VA (en) 2021-08-30
BR112021013944A8 (pt) 2023-02-07
KR20210121077A (ko) 2021-10-07
JP2022517029A (ja) 2022-03-03
CN113508129A (zh) 2021-10-15
JP2025000723A (ja) 2025-01-07
JP7645185B2 (ja) 2025-03-13
ES3011707T3 (en) 2025-04-08
IL284868B2 (en) 2025-09-01
CN113508129B (zh) 2025-02-18
EP3911670C0 (en) 2024-12-25
AU2020208909B2 (en) 2025-02-20
IL284868A (en) 2021-08-31
IL284868B1 (en) 2025-05-01
EP3911670B1 (en) 2024-12-25
AU2020208909A1 (en) 2021-07-29
WO2020148338A1 (en) 2020-07-23
MX2021008525A (es) 2021-11-12

Similar Documents

Publication Publication Date Title
BR112021017339A2 (en:Method)
BR112021017637A2 (en:Method)
BR112021017939A2 (en:Method)
BR112021017892A2 (en:Method)
BR112021017738A2 (en:Method)
BR112021017782A2 (en:Method)
BR112021016821A2 (en:Method)
BR112021017728A2 (en:Method)
BR112021017234A2 (en:Method)
BR112021017703A2 (en:Method)
BR112021016996A2 (en:Method)
BR112021017732A2 (en:Method)
BR112021015080A2 (en:Method)
BR112021017355A2 (en:Method)
BR112021018093A2 (en:Method)
BR112021018102A2 (en:Method)
BR112021017173A2 (en:Method)
BR112021017310A2 (en:Method)
BR112021017083A2 (en:Method)
BR112021013944A2 (en:Method)
BR112021013128A2 (en:Method)
BR112021018484A2 (en:Method)
BR112021017949A2 (en:Method)
BR112021018084A2 (en:Method)
BR112021017010A2 (en:Method)

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; NANTES UNIVERSITE (FR)